XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net loss $ (14,163) $ (20,055)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 734 696
Non-cash lease expense 81 87
Change in fair value of preferred stock warrant liability 7,378
Change in fair value of Clene Nanomedicine contingent earn-out (18,072)
Change in fair value of Initial Shareholders contingent earn-out (1,710)
Change in fair value of derivative (29)
Change in fair value of common stock warrant liability (547)
Gain on termination of lease (51)
Stock-based compensation expense 9,945 554
Gain on extinguishment of notes payable (647)
Loss on extinguishment of convertible notes payable 540
Accretion of debt discount 179
Increase (decrease) in interest accrued on notes payable (134) 399
Changes in operating assets and liabilities:    
Inventory 150 (32)
Accounts receivable (48) (21)
Prepaid expenses and other current assets (1,230) (2,112)
Accounts payable 446 (242)
Accrued liabilities 511 (335)
Payable to related parties (131)
Deferred revenue from related parties 112
Deferred income tax (192)
Operating lease obligations (142) (58)
Net cash used in operating activities (25,018) (13,121)
Cash flows from investing activities:    
Purchases of property and equipment (661) (269)
Net cash used in investing activities (661) (269)
Cash flows from financing activities:    
Proceeds from exercise of stock options 427 2
Proceeds from issuance of convertible notes payable 6,125
Proceeds from warrants exercised 10
Payments of finance lease obligations (117) (156)
Proceeds from the private placement 9,250
Proceeds from the issuance of notes payable 20,000 652
Payments of debt issuance costs (534)
Payments of notes payable (5)
Payments of deferred transaction costs (1,901) (310)
Proceeds from issuance of Series D Preferred Stock, net of issuance costs 35,051
Net cash provided by financing activities 27,130 41,364
Effect of foreign exchange rate changes on cash (116) 19
Net increase in cash and restricted cash 1,335 27,993
Cash and restricted cash – beginning of period 59,275 8,788
Cash and restricted cash – end of period 60,610 36,781
Reconciliation of cash and restricted cash to the condensed consolidated balance sheets    
Cash 60,552 36,781
Restricted cash 58
Cash and restricted cash 60,610 36,781
Supplemental disclosure of non-cash investing and financing activities:    
Warrant liability recorded at issuance of notes payable 1,457
Lease liability arising from obtaining right-of-use assets, leasehold improvements, and lease incentives 2,492 820
Lease liability settled through termination of lease 349
Issuance of derivative instrument related to convertible notes (705)
Issuance of Series D Preferred Stock upon extinguishment of convertible promissory notes 5,675
Extinguishment of derivative liability in connection with extinguishment of convertible promissory notes 676
Deferred offering costs in accrued liabilities 2,011
Supplemental disclosure:    
Cash paid for interest expense $ 631 $ 30